Abstract:Cassidy Nguyen, 1, &ast Guilherme Kuceki, 1, &ast Michael Birdsall, 1 Dev Ram Sahni, 2, 3 Vikram Nath Sahni, 2 Christopher M Hull 2 1 School of Medicine, University of Utah, Salt Lake City, UT, USA; 2 Department of Dermatology, University of Utah Health, Salt Lake City, UT, USA; 3 Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA &astThese authors contributed equally to this work Correspondence: Dev Ram Sahni, Brigham and Women's Hospital, 221 Longwood Ave, Boston, MA, 02115, USA, Tel +16177324918, Email Rosacea is a common chronic dermatosis. Clinically, rosacea can present with flushing, erythema, papules, pustules, telangiectasias, phymatous changes, pruritus, burning, and stinging. In 2017, the National Rosacea Society Expert Committee recommended a phenotype-based classification for therapy. In this review, we identify monotherapies and multimodal treatment approaches for the clinical management of rosacea including topical, systemic, laser and light, alternative, and combination therapies. Keywords: combination therapy, management, monotherapy, rosacea, therapy, treatment Rosacea is a common chronic dermatosis with a prevalence of approximately 5.46% of the global population. 1 However, prevalence is theoretically higher as these percentages do not account for patients with milder, unrecognized disease. The first reported account of rosacea was in the 14th century by Dr Guy de Chauliac, a French surgeon, who described "red lesions on the face" and termed the condition "goutterose"—French for "pink droplet"—or "couperose", which remains as a term still used in French medical language. 1 Onset of illness commonly emerges in middle to late adulthood and affects males and females equally, with a predominance of disease occurring in Northern European populations. 2 Rosacea clinically presents with centrofacial erythema, prominent blood vessels, papules, and pustules. 3 In 2002, the National Rosacea Society Expert Committee developed a subtype-based standardized classification system. 4 The proportions of those affected by rosacea were found to be 56.7% (95% CI, 51.4–62.0%) for erythematotelangiectatic rosacea (ETR), 43.2% (95% CI, 38.8–47.6%) for the papulopustular subtype (PPR), 7.4% (95% CI, 6.1–8.9%) the phymatous subtype, and 11.1% (95% CI, 6.7–16.3%) the ocular subtype. 5 These subjective subtype designations made it difficult to categorize patients considering the overlap of symptoms between categories. Over the next 15 years, further insights into the pathogenesis and pathophysiology of rosacea led to the 2017 updated classification guidelines that provided a phenotype-based approach that aimed to describe more explicit parameters based on clinical presentation and their respective, diagnostic positive predictive values. 6 Instead of subtyping, the new classification system groups pathognomonic centrofacial erythema with major phenotypic criteria—papules, pustules, flushing, telangiectasia, and ocular involvement. Secondary phenotypes include burning, stinging, edema, and dry appearance. 6 These new guidelines facilitate the individualization and customization of treatment for each patient. The pathophysiology of rosacea is not entirely understood, but a multifactorial component is suspected with both genetic and environmental factors contributing to its development and progression. 7 Mechanisms of disease propagation include both contribution from innate and adaptive immunity. Inflammation may be caused by dysregulation of proinflammatory cytokines (eg, IL-1, IL-3, and IL-8), alteration and dilation of small blood vessels, imbalances in the skin's microbiome, genetic factors, and environmental triggers. 1,7,8 There remains a lack of consensus on whether varying subtypes of rosacea are individualized clinical entities or if they represent a spectrum of disease progression. However, emerging studies have revealed that the diverse features of this disease and its numerous phenotypes may be part of a range of inflammation that is detectable both histologically and biochemically. 9–12 UV light induces the production of vitamin D, which promotes cathelicidin expression in keratinocytes. Biochemically, patients with rosacea exhibit aberrant expression of cathelicidin, kallikrein-related peptidase 5 (KLK5), and subsequent cleaved product LL-37. The aberrantly cleaved LL-37 leads to disruption in regulation of leukocyte chemotaxis, angiogenesis (facilitated by CXCR chemokine receptor-ligands), expression of extracellular matrix components, and activation of NF-κB, which clinically correlate with the characteristic facial erythema -Abstract Truncated-

Rosacea Core Domain Set for Clinical Trials and Practice

Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS)

CHronic Rhinosinusitis Outcome MEasures (CHROME), developing a core outcome set for trials of interventions in chronic rhinosinusitis

A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials

Current research and clinical trends in rosacea pathogenesis

A comprehensive epidemiological study of rosacea in Germany

Rosacea: New Concepts in Classification and Treatment

Protocol of a scoping review of outcome domains in dermatology

Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes

[Rosacea 2009 : new advances in pathophysiology, clinical staging and therapeutic strategies]

Expert consensus achieved on a working core outcome set for cutaneous lupus erythematosus research in survey following the 5th International Conference on Cutaneous Lupus Erythematosus (ICCLE)

A Cosmetic Regimen Formulated to Address the Multi-Modal Pathogenesis of Rosacea Demonstrates Efficacy for Treating Facial Redness and Skin's Appearance

Global rosacea treatment guidelines and expert consensus points: The differences

Consensus on the definitions and descriptions of the domains of the OMERACT Core Outcome Set for shared decision making interventions in rheumatology trials

Core outcome set for cardio-oncology: development of a set of outcomes for the cardiovascular assessment and monitoring of cancer patients and survivors

Prevalence of ocular manifestations in cutaneous rosacea: Protocol for a systematic review and meta-analysis

Efficacy of Treatments in Reducing Facial Erythema in Rosacea: A Systematic Review

Rosacea: Practical Guidance and Challenges for Clinical Management

Efficacy of Treatments in Reducing Inflammatory Lesion Count in Rosacea: A Systematic Review

Postinflammatory hyperpigmentation: protocol for development of a core outcome set for clinical trials

Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach